Insiders · VRNA

Michael Austwick

Director at Verona Pharma plc (VRNA) since February 2024

Michael Austwick has filed 5 insider reports with the SEC since February 2024, as director at Verona Pharma plc (VRNA). Michael Austwick made no open-market purchases or sales in the last 12 months. The latest filing, on October 8, 2025, reports sale back to the company and exercise or conversion of a derivative at Verona Pharma plc (VRNA).

Filings
5
Companies
1
Bought on market
None
Sold on market
$148K

Companies where Michael Austwick is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Verona Pharma plc logo
VRNA
Verona Pharma plc
Directorsince February 20240$148KOct 8, 2025

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Michael Austwick with

Other insiders at the same companies

Questions about Michael Austwick

What is Michael Austwick's role at Verona Pharma plc?
Michael Austwick reports to the SEC as director at Verona Pharma plc (VRNA), according to the latest filing on October 8, 2025.
Has Michael Austwick bought or sold stock recently?
The most recent open-market sale was on August 1, 2025: sold 11,288 shares of Verona Pharma plc (VRNA) for $148K at an average of $13.14.
How do I get alerts when Michael Austwick files?
Follow Michael Austwick on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Michael Austwick (SEC CIK 0002009903). Totals count each trade once, skipping amendments whose original is on file, from Feb 2, 2024 on. View on SEC EDGAR · Get this as JSON